If you have patients with relapsed or refractory CD19-positive leukemia or lymphoma, they may be eligible for the SENTRY-CD19 Study, which will evaluate a one-time investigational gene therapy called VNX-101. Learn more about the SENTRY-CD19 study.
Get StartedThe purpose of the SENTRY-CD19 study is to evaluate an investigational gene therapy called VNX-101. This treatment is delivered as a one-time infusion and designed to help the immune system recognize and destroy cancer cells with a marker called CD19. It may improve outcomes for people whose leukemia or lymphoma has come back or hasn't responded to other treatments.
Visit the research site to receive the one-time infusion of the study medication. Participants may be required to stay in a clinic or hospital for 1–2 nights after receiving the infusion for observation. After receiving the study medication, they will visit the research site weekly for the first 56 days (approximately 8 visits). They will then be followed up with monthly, every 2 months, every 4 months, and every 6 months for the first 4 years, followed by yearly check-ins for 5 to 15 years. This may include phone call follow-ups from the study doctor during years 6-15.
Unlike most cancer treatments that require repeated cycles of chemotherapy or custom-made cell therapies, the VNX-101 study is testing a single-dose gene therapy designed to help the body continuously fight CD19-positive cancer cells over time, without the need for repeated treatments.
VNX-101 combines the best attributes of CAR-T and blinatumomab (current standard-of-care therapies) into one product, as an off-the-shelf, single-dose therapy with a long-lasting effect.
If you have a patient who might be interested and potentially eligible for this study — or if someone comes to mind — you can:
Complete the Contact PatientWing form below. We’ll contact you and discuss how your patient can get involved.
Share this study directly with your patient so they can apply on their own. Provide them with this website so they can read about the study and fill out a pre-screen questionnaire.
If you have patients who may be a good fit for the study or are interested in being an investigator (working on this study), please contact PatientWing (using the form below)!